PTO/SB/08a (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO			Complete if Known		
				Application Number	10/541,614
INFORMATION DISCLOSURE				Filing Date	April 27, 2006
STATEMENT BY APPLICANT			ANT	First Named Inventor	PATERSON, Yvonne
				Art Unit	1645
(use as many sheets as necessary)			v)	Examiner Name	PORTNER, VIRGINIA ALLEN
Sheet	1	of	2	Attorney Docket Number	P-7772-US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No. 1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document		
	Α	US-5,830,702	11-03-1998	Portnoy et al.		
	В	US-6,051,237	04-18-2000	Paterson et al.		
	С	US-4,256,108	03-17-1981	Theeuwes		
	D	US-4,160,452	07-10-1979	Theeuwes		
	E	US-4,265,874	05-05-1981	Bonsen et al.		
	F	US-3,328,252	06-27-1967	Mora et al.		
	G	US-2002/0177569	11-28-2002	Kaufmann et al.		
	Н	US- 5,628,994	05-13-1997	Kaper et al.		
	i i	US- 5,861,163	01-19-1999	Kim et al.		
		US-		·		
		US-				
	T	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS					
Examiner	Cito	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns,	-6
Initials*	Cite No. 1	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	INIIVI-DD-Y Y Y Y	Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures Appear	
17	J	WO 01/25399	04-12-2001	Vion Pharmaceuticals Inc.		
					,	
	1					

Examiner	Date
Signature	Considered

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.qov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
				Application Number	10/541,614
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			SURE	Filing Date	April 27, 2006
			CANT	First Named Inventor	PATERSON, Yvonne
				Art Unit	1645
(use as many sheets as necessary)		Examiner Name	PORTNER, VIRGINIA ALLEN		
Sheet	2	of	2	Attorney Docket Number	P-7772-US

		NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	K	BERCHE et al. (1988) "Invasiveness and intracellular growth of Listeria monocytogenes." Infection 16:145-148.	
	L	FOLEY et al. (2001) "Candidatus Mycoplasma haemominutum, a low virulence	
		epierythrocytic parasite of cats" International Journal of Systematic and Evolutionary Microbiology, 51(3):815-817.	I
	М	GOOSSENS et al. (1995), "Attenuated Listeria monocytogenes as a live vector for	
	•	induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus." Int. Immunol. 7:797-802.	
	N	GUNN et al.(2001) "Two Listeria monocytogenes vaccine vectors that express different	
		molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16." J. Immunol. 167:6471-6479.	
	0	HARRIS et al. (1986) "Molecular basis for heterogeneity of the human p53 protein." Mol. Cell. Biol. 6:4650-4656.	
	Р	IKONOMIDIS et al. (1997) "Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines." Vaccine 15:433-440.	
	Q	KAUFMANN (1993) "Immunity to intracellular bacteria" Ann. Rev. Immunol. 11:129-163.	
	R	KLEANTHOUS, H et al. (2001) "Sterilizing immunity against experimental Helicobater pylori infection is challenge-strain dependent." Vaccine 14, 19(32):4883-4895.	
	s	MANKOSKI et al. (1999) "flaA mRNA transcription level correlates with Helicobactor pyloricolonisation efficiency in gnotobiotic piglets." Journal of Medical Microbiology, 48(4):395-399.	
	T	MATA et al. (2001) "Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge." Vaccine 19:1435-1445.	
	U	MERINO et al. (2002) "A hypermutator phenotype a attenuates the virulence of Listeria monocytogens in a mouse model." Molecular Microbiology, 44(3):877-887.	
	V	PAN et al. (1995), "A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours." Nat. Med. 1:471-477.	
	W	PATERSON et al. (1996) "Recombinant Listeria monocytogenes cancer vaccines." Curr. Opin. Immunol. 8:664-669.	
	X	SHEN et al. (1995) "Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity." Proc. Natl. Acad. Sci. USA 92:3987-3991.	
	Y	VAHIDY et al. (1996) "A comparative study of unpassaged and animal passaged cultures of Listeria monocytogenes in rabbits." Ann Acad Med. Singapore 25:139-553.	
Examiner		Date Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Indude copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.